Are there evidence‑based studies or guidance on using upadacitinib (Rinvoq) for patients with ulcerative colitis and primary sclerosing cholangitis?

Using Upadacitinib in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis

There is no direct evidence-based guidance on using upadacitinib specifically in patients with both ulcerative colitis and PSC, but the drug can be used with extreme caution and intensive hepatic monitoring given the known risk of liver enzyme elevations and the underlying liver disease.

Current Evidence Landscape

Guideline Positioning

The 2024 AGA guidelines classify upadacitinib as a higher efficacy medication for moderate-to-severe UC in advanced therapy-naïve patients 1. However, these guidelines make no specific mention of PSC as a consideration or contraindication. The 2022 EASL guidelines on sclerosing cholangitis 2 do not address JAK inhibitors or upadacitinib at all, focusing instead on immunosuppression for IgG4-related cholangiopathy and UDCA for various cholangiopathies.

FDA Label Warnings

The FDA label for upadacitinib 3 documents that elevated liver enzymes occurred in 2-3% of UC patients during induction (vs 0% placebo) and 4% of patients on 30mg maintenance (vs 0.8% placebo). Specifically:

• ALT elevations ≥3x ULN: 1.5% (induction), 4% (30mg maintenance)
• ALT elevations ≥5x ULN: 0.4% (induction), 0.8% (30mg maintenance)

This hepatotoxicity signal is particularly concerning in PSC patients who already have compromised biliary function and are at risk for progressive liver disease.

The Critical PSC-Specific Evidence

The only published data on upadacitinib in patients with liver disease comes from a 2025 case series of post-liver transplant IBD patients 4. This small study is highly relevant:

• 4 patients (3 Crohn's, 1 UC) received upadacitinib after liver transplantation
• 3 of 4 patients (75%) developed liver enzyme elevations
• 2 patients discontinued upadacitinib due to these elevations
• One patient required liver biopsy to rule out rejection
• Only 2 of 4 achieved therapeutic goals

This represents the strongest signal that upadacitinib poses significant hepatic risk in patients with underlying liver disease, even in the controlled post-transplant setting with close monitoring.

Clinical Decision Algorithm

When to Consider Upadacitinib in UC + PSC:

1. Patient has failed multiple biologics (TNF antagonists, vedolizumab, ustekinumab) and other JAK inhibitors
2. Baseline liver function is compensated (Child-Pugh A, no cirrhosis, bilirubin <2x ULN, ALT/AST <3x ULN)
3. No evidence of dominant stricture requiring intervention
4. Patient is not a liver transplant candidate in the near term

Absolute Contraindications in PSC Context:

• Decompensated cirrhosis (any Child-Pugh B or C)
• Baseline ALT or AST >3x ULN
• Recent bacterial cholangitis (within 3 months)
• Concurrent hepatotoxic medications that cannot be stopped

Monitoring Protocol (More Intensive Than Standard):

• Baseline: Complete hepatic panel, CBC, lipid panel
• Weeks 2,4,6,8: ALT, AST, alkaline phosphatase, bilirubin
• Monthly thereafter for 6 months, then every 2-3 months
• Immediate discontinuation if: ALT/AST >5x ULN, bilirubin doubles, or any signs of hepatic decompensation

Alternative Considerations

Given the hepatotoxicity concerns, consider these alternatives first in UC + PSC patients:

1. Vedolizumab - gut-selective, minimal hepatic metabolism, no reported hepatotoxicity signal
2. Ozanimod or etrasimod (S1P modulators) - classified as higher efficacy by AGA 1, better hepatic safety profile
3. Risankizumab or guselkumab (IL-23 inhibitors) - newer higher efficacy options without significant liver concerns

Real-World Efficacy Data

While real-world studies show impressive efficacy in general UC populations (68.4% clinical remission at week 8 5, sustained remission through 3 years 6), none of these studies specifically addressed or stratified outcomes in PSC patients. The post-transplant case series 4 suggests efficacy may be compromised by the need for early discontinuation due to hepatotoxicity.

Key Pitfalls to Avoid

• Do not assume standard UC monitoring is sufficient - PSC requires more frequent and comprehensive hepatic surveillance
• Do not continue therapy if ALT/AST trend upward even if below discontinuation thresholds - PSC patients have less hepatic reserve
• Do not use upadacitinib as first-line in UC + PSC - exhaust safer alternatives first given the 75% hepatotoxicity rate in the only relevant study 4
• Coordinate care with hepatology - this is not a decision to make in isolation

The risk-benefit calculation fundamentally shifts in PSC patients, and upadacitinib should be reserved as a last-resort option with exceptional monitoring.